Expanded access to viral load testing and use of second line regimens in Haiti: time trends from 2010–2017

BMC Infectious Diseases

Table 5 Association between VL Testing and Second-Line Regimen Switching (n = 66,042)^a

		N	HR	95% CI	p-value
VL test status	No test	36,442	1.0	Ref.	Ref.
	Suppressed	19,829	0.4	(0.3, 0.5)	< 0.001
	Unsuppressed	6022	5.6	(4.9, 6.5)	< 0.001
	Re-suppressed	1328	2.3	(1.3, 4.4)	< 0.01
	Confirmed failure	2421	22.2	(18.8, 26.3)	< 0.001
Age group	16~24	8173	1.0	Ref.	Ref.
	25~34	22,335	1.0	(0.9, 1.2)	0.89
	35~44	18,828	0.9	(0.8, 1.1)	0.45
	45~54	10,778	0.8	(0.7, 1.0)	0.09
	> 55	5928	0.7	(0.6, 0.9)	< 0.01
Gender	Female	42,623	1.0	Ref.	Ref.
Gender	Male	23,419	1.4	(1.2, 1.5)	< 0.001
Baseline WHO stage	Stage 1	12,879	1.0	Ref.	Ref.
	Stage 2	10,983	1.4	(1.1, 1.8)	< 0.01
	Stage 3	14,217	1.9	(1.6, 2.4)	< 0.001
	Stage 4	21,814	3.2	(2.6, 3.9)	< 0.001
	Missing	6149	1.4	(1.1, 1.9)	0.01
Year of ART initiation	2010–2012	18,418	1.0	Ref.	Ref.
	2013	10,812	0.7	(0.6, 0.8)	< 0.001
	2014	11,629	0.6	(0.5, 0.7)	< 0.001
	2015	10,483	0.8	(0.6, 0.9)	< 0.01
	2016–2017	14,700	0.5	(0.4, 0.7)	< 0.001

^aIncludes all ART patients (see Table 1 for characteristics of 66,042 ART patients)

ISSN: 1471-2334